In detail, as shown in Fig. 3A, among HR-positive/HER2-negative cases, 21.4% switched from HER2 0 to HER2-low expression, while 19.0% converted from HER2-low to HER2 0 breast cancer. Here, ERBB2 is linked to breast cancer.